Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2024-08-21 00:00:00 ET · period of report 2024-08-19 · accession 0001415889-24-021869 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-08-21 | 2024-08-19+ | QNCX | Hannah Brendan | Chief BUSINESS Off. AND COO | P - Purchase | $0.6209 | +38.9K | 265.7K | +17% | +$24.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-19 | P | A | 2,155 | $0.58 | 259,771 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-20 | P | A | 2,500 | $0.61 | 262,271 | D | — | — | |
| 3 | Common | Common Stock | 2024-08-21 | P | A | 23,565 | $0.63 | 296,540 | D | — | — | |
| 4 | Common | Common Stock | 2024-08-21 | P | A | 2,280 | $0.61 | 267,975 | D | — | — | |
| 5 | Common | Common Stock | 2024-08-21 | P | A | 5,000 | $0.62 | 272,975 | D | — | — | |
| 6 | Common | Common Stock | 2024-08-20 | P | A | 3,424 | $0.6 | 265,695 | D | — | — |